Progentos Therapeutics' CEO Chris Loose (L) and Chief Scientific Officer Sanjay Magavi
Progentos emerges with $65M for multiple sclerosis trials with IP from Frequency
A new biotech emerged to take forward the lead preclinical work developed by Frequency Therapeutics, a regenerative medicines company that gave up …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
